Skip to main content
SpringerLink
Log in

Imatninib versus dasatinib, nilotinib: lower risk of ED visits and costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Cole AL, et al. Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib. JCO Oncology Practice : 20 Mar 2020. Available from: URL: https://doi.org/10.1200/JOP.19.00301

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Imatninib versus dasatinib, nilotinib: lower risk of ED visits and costs. PharmacoEcon Outcomes News 851, 24 (2020). https://doi.org/10.1007/s40274-020-6747-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6747-z

Search

Navigation